Commitments (Details Narrative) - USD ($) |
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
Apr. 16, 2019 |
Apr. 02, 2019 |
Dec. 15, 2016 |
Sep. 12, 2016 |
Feb. 19, 2016 |
Nov. 01, 2013 |
Dec. 31, 2019 |
|
| Operating lease term | 7 years | 10 years | |||||
| Lease monthly rent expense | $ 43,000 | $ 13,000 | |||||
| Increase of rent expenses | 64,000 | 14,000 | |||||
| Initial security deposit | 586,000 | 300,000 | |||||
| Reduced deposit amount | 486,000 | $ 50,000 | |||||
| Remaining balance lease term amount | 200,000 | ||||||
| Revenue recognition, milestone fee on achieving sales threshold | $ 100,000 | ||||||
| License costs | $ 10,000 | ||||||
| License agreement, description | The Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $100,000 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of initially $10,000, increasing to $50,000 over the term of the license agreement. | ||||||
| Matinas BioPharma Nanotechnologies, Inc. [Member] | |||||||
| Business acquisition equity interest issuable, description | Pursuant to the terms of the merger agreement with Aquarius Biotechnologies, Inc., we may be required to issue up to an additional 3,000,000 shares of our common stock upon the achievement of certain milestones. The milestone consideration consists of (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius' proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius' proprietary cochleate delivery technology. The Company concluded that the contingent share issuance represented equity settled contingent consideration and have recorded the amounts to equity since inception. None of these milestones have yet been reached, and accordingly, as of December 31, 2019 no additional shares have been issued. | ||||||
| Number of shares issued for aquisition | |||||||
| Series A Preferred Stock [Member] | |||||||
| Royalty payment rights, description | The Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the "Royalty Payment Rights") equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $10 million per calendar year. | The Series A Preferred Stock includes the right, as a group, to receive: (i) a royalty of 4.5% of the net sales of the Company's MAT2203 and MAT2501 product candidates, in each case from and after the date, respectively, such product candidate has received FDA or EMA approval, and (ii) a royalty of 7.5% of the proceeds, if any, received by the Company in connection with the licensing or other disposition by the Company of MAT2203 and/or MAT2501 ("Royalty Payment Rights"). | |||||
| Royalty payment rights expire description | The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033. | ||||||
| Cooperative Research and Development Agreements [Member] | |||||||
| Remaining balance lease term amount | $ 200,000 | ||||||
| Funds provide for support | $ 157,405 | ||||||
| Initial term | 3 years | 3 years | 3 years | ||||
| Other commitment | $ 200,000 | ||||||
| One Anniversaries [Member] | |||||||
| Remaining balance lease term amount | 100,000 | ||||||
| Two Anniversaries [Member] | |||||||
| Remaining balance lease term amount | 100,000 | ||||||
| Three Anniversaries [Member] | |||||||
| Remaining balance lease term amount | $ 86,000 | ||||||
| Maximum [Member] | |||||||
| Operating lease term | 10 years | ||||||
| License costs | $ 50,000 | ||||||
| Maximum [Member] | Series A Preferred Stock [Member] | |||||||
| Accrued royalties | $ 35,000,000 | ||||||
| Maximum [Member] | 4.5% of Net Sales [Member] | Series A Preferred Stock [Member] | |||||||
| Accrued royalties | 25,000,000 | ||||||
| Maximum [Member] | 7.5% of Net Sales [Member] | Series A Preferred Stock [Member] | |||||||
| Accrued royalties | $ 10,000,000 | ||||||
| Minimum [Member] | |||||||
| Operating lease term | 3 months |